Quiver Bioscience received an undisclosed investment to advance its UBE3A antisense oligonucleotide program toward a development candidate for the treatment of chromosome 15q duplication syndrome, a rare neurodevelopmental disorder.
All entries for: Quiver Bioscience
July 1, 2025
Quiver Bioscience
Investment
Quiver Bioscience secured $0.91 million investment to enhance its CNS genetic medicine discovery platform and improve safety prediction for antisense oligonucleotide therapeutics. The company’s portfolio includes programs advancing precision treatments for both common and rare neurological disorders, including Dup15q syndrome, Fragile X syndrome, and KCNT1-related epilepsy.
Disease Area: Rare Diseases